The United Kingdom has been investing in precision oncology for years now and it is becoming more prevalent. The NHS provides funding for precision oncology research in order to improve care for cancer patients. This includes the development of new drugs and treatments, as well as high-tech imaging techniques and genetic analysis. One example of this could be the NIHR Manchester Biomedical Research Centre which is hosted by Manchester University NHS Foundation Trust & The University of Manchester.
Our Platforms: RSA2™ and OncoCrest™
RSA2™: Accelerating Insights in Bioinformatics
Experience a seamless journey from data to discovery with RSA2™. Dive into the world of automated bioinformatics analysis, empowering you to unravel complex genetic insights, predict 3D protein structures, and streamline your research processes. Explore RSA2™ and revolutionize your approach to precision medicine and drug development.
OncoCrest™: Precision Oncology Redefined
Elevate your oncology research with OncoCrest™, where AI-powered predictive insights guide treatment decisions and advance cancer care. Harness the potential of fusion event identification, protein folding prediction, and survival analysis to drive precision medicine forward. Embark on a journey to redefine personalized cancer research with OncoCrest™.